ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1764 • 2019 ACR/ARP Annual Meeting

    CCL25, a Novel Fibroblast and Macrophage Chemoattractant That Potentiates RA Bone Erosion

    Sadiq Umar1, Katrien Raemdonck 1, Karol Palasiewicz 1, Michael Volin 2, Shiva Arami 1, Suncica Volkov 1, Nadera Sweiss 1, M Amin 3 and Shiva shahrara 1, 1University of Illinois at chicago, Chicago, IL, 2Department of Microbiology & Immunology, Midwestern University, Downer Grove, IL, 3University of Michigan, Ann Arbor, MI

    Background/Purpose: Background/Purpose: CCL25 and its receptor CCR9 have been detected in the inflamed joint; however their role is undefined in rheumatoid arthritis (RA). Hence studies…
  • Abstract Number: 1765 • 2019 ACR/ARP Annual Meeting

    Interferon-gamma Supports Transcriptional Activity of BIRC5 in CD4+ T Cells in Established Rheumatoid Arthritis

    Malin Erlandsson 1, Karin Andersson 1, Nisha Nair 2, Anastasius Damdimopoulos 3, Sofia Silfverswärd 1, Rille Pullerits 1, Anne Barton 2 and Maria Bokarewa1, 1Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden, 2Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK, Manchester, United Kingdom, 3Department of Biosciences and Nutrition, Karolinska Institute, Solna, Sweden, Stockholm, Sweden

    Background/Purpose: It is known that rheumatoid arthritis (RA) should be treated early and a delay in treatment increases the rate of treatment non-response, joint damage,…
  • Abstract Number: 1766 • 2019 ACR/ARP Annual Meeting

    GM-CSF Is a Pro-Inflammatory Cytokine in Experimental Vasculitis of Medium and Large Arteries

    Ryu Watanabe 1, Hui Zhang 2, Toshihisa Maeda 3, Mitsuhiro Akiyama 2, Rohan Gandhi 4, John Paolini 5, Gerald Berry 1 and Cornelia Weyand2, 1Stanford University, Stanford, 2Stanford University, Stanford, CA, 3Matsubara Mayflower Hospital, Kobe, Japan, 4Kiniska Pharmaceuticals, San Diego, 5Kiniska Pharmaceuticals, Lexington, MA

    Background/Purpose: Giant Cell Arteritis (GCA) is a granulomatous vasculitis with tissue tropism for medium and large arteries. Macrophages are a key cellular component of the…
  • Abstract Number: 1767 • 2019 ACR/ARP Annual Meeting

    Biomarker Profiling Reveals Novel Mechanistic Insights into Ustekinumab Therapeutic Responses in Systemic Lupus Erythematosus

    Matteo Cesaroni1, Loqmane Seridi 1, Jarrat Jordan 1, Kristen Sweet 1, Keying Ma 1, Carol Franks 1, Jessica Schreiter 1, Peter Lipsky 2, Ronald van Vollenhoven 3, Bevra Hahn 4, Shawn Rose 1, Frédéric Baribaud 1, Matthew Loza 1, Kim Campbell 1 and George Tsokos 5, 1Janssen Research & Development, LLC, Spring House, PA, 2AMPEL BioSolutions, LLC, Charlottesville, VA, 3Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 4University of California, Los Angeles, CA, 5Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease that causes progressive organ damage. The cytokines type I interferon (IFN-I), IL-12 and IL-23 have…
  • Abstract Number: 1768 • 2019 ACR/ARP Annual Meeting

    A First-in-class Selective and Potent IRAK4 Degrader Demonstrates Robust in Vitro and in Vivo Inhibition of TLR/IL-1R Activation and Inflammation

    Veronica Campbell1, Joseph Kelleher 1, Jesse Chen 1, Jared Gollob 2, Nan Ji 2, Christine Klaus 2, Christine Loh 2, Michelle mayo 2, Alice McDonald 2, Haojing Rong 2, Scott Rusin 2, Kirti Sharma 2, Matt Weiss 2, Karen Yuan 2, Duncan Walker 2, Xiaozhang Zheng 2, Anthony Slavin 2 and Nello Mainolfi 2, 1Kymera Therapeutics, cambridge, MA, 2Kymera Therapeutics, Cambridge

    Background/Purpose: IL-1R/TLR activation plays a central role in the pathophysiology of multiple autoimmune and inflammatory diseases driven by the IL-1 family of cytokines and by…
  • Abstract Number: 1769 • 2019 ACR/ARP Annual Meeting

    Myosin Regulation of TNF Receptor 2 Signaling May Contribute to Anti-TNF Therapy Response

    Unnikrishnan M Chandrasekharan1, Jennifer Harvey 2, Mackenzie Dunlap 2, Marcia Leon Rabanal 2, Vandana Rai 2 and M. Elaine Husni 3, 1Cleveland clinic foundation, Cleveland, OH, 2Cleveland clinic, Cleveland, 3Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Background/Purpose:Anti-TNF agents have revolutionized the clinical outcomes of patients with  rheumatoid and psoriatic diseases. However, up to 40% of patients do not respond or…
  • Abstract Number: 1770 • 2019 ACR/ARP Annual Meeting

    Experimental Rheumatoid Joint Ameliorated by CRISPR Interference Targeting Long Non-coding RNA H19 Through Wnt Signaling Inactivation

    Chrong-Reen Wang1, Shih-Yao Chen 1, Yu-Chi Chou 2, Chao-Liang Wu 3, Yu-Ting Lo 1 and Ai-Li Shiau 4, 1National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), 2Genomics Research Center, Academia Sinica, Taipei, Taiwan (Republic of China), 3National Cheng Kung University Medical College, Tainan, Taiwan (Republic of China), 4National Cheng Kung University Medical College, Tainan, Taiwan (Republic of China)

    Background/Purpose: Long non-coding RNAs (lncRNAs) participate in the rheumatoid arthritis (RA) pathogenesis. The aim of this study was to examine the lncRNA H19 and HOTAIR…
  • Abstract Number: 1771 • 2019 ACR/ARP Annual Meeting

    MyD88 S209R Enhances Inflammation in Mouse Models of Arthritis

    Sufia Bakshi1, Anders Lindstedt 2, Malika Waschmann 3, Wanxia Tsai 1, Robert Colbert 4 and Keith Sikora 1, 1National Institutes of Health, Bethesda, MD, 2NIH, Bethesda, MD, 3Oregon Health and Science University, Portland, OR, 4Pediatric Clinical Trials Unit, Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD

    Background/Purpose: MyD88 is a critical adaptor protein that connects Toll-like and IL-1 receptor signaling to activation of NF-kB. We previously reported a heterozygous de novo gain-of-function mutation in MYD88 (S222R)…
  • Abstract Number: 1772 • 2019 ACR/ARP Annual Meeting

    Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice

    Arisa Yaekura1, Kanta Morii 2, Yuto Oketani 3, Ikumi Okumura 2, Kenta Kaneshiro 4, Kohsuke Yoshida 2, Yoshiko Kawasaki 5, Nao Shibanuma 5, Yoshitada Sakai 6 and Akira Hashiramoto 2, 1Kobe University Graduate School of Health Sciences, Kawanishi, Hyogo, Japan, 2Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan, 3Kobe University Graduate School of Health Sciences, Himeji, Hyogo, Japan, 4Kobe University Graduate School of Health Sciences, Osaka, Osaka, Japan, 5Kobe Kaisei Hospital, Kobe, Hyogo, Japan, 6Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan

    Background/Purpose: Diurnal variations are observed in symptoms of rheumatoid arthritis (RA). Among them, “morning stiffness of joints” is closely reflects the daily medical condition of…
  • Abstract Number: 1773 • 2019 ACR/ARP Annual Meeting

    The Card9-Neutrophil Signaling Axis Is Critical to Induction of Th17-Mediated Arthritis in SKG Mice

    Ruth Napier1, Ellen Lee 1, Emily Vance 1, Beatitude Steffen 2, Shimon Sakaguchi 3 and Holly Rosenzweig 4, 1Oregon Health & Science University and Portland VA Hospital, Portland, OR, 2Oregon Health & Science University and Portland VA Hospital, Portland, 3Osaka University, Osaka, Japan, 4Oregon Health & Science University and Portland VA Hospital, Oregon

    Background/Purpose: Caspase recruitment domain-containing protein 9 (CARD9) is an adaptor protein downstream of C-type lectin receptor signaling within myeloid cells. CARD9 is critical for anti-fungal immunity;…
  • Abstract Number: 1774 • 2019 ACR/ARP Annual Meeting

    Potential Involvement of OX40 Expressing Tfh Cells on Regulation of Autoantibody Sialylation in Experimental and Rheumatoid Arthritis

    Izumi Kurata1, Isao Matsumoto 1, Natsuko Mikami 1, Ayako Ohyama 1, Atsumu Osada 1, Yuya Kondo 1, Hiroto Tsuboi 1 and Takayuki Sumida 1, 1Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

    Background/Purpose: Recently, IL-23-Th17 cells axis and hyposialylation of antibodies were proved to be linked to experimental and rheumatoid arthritis. However it remains uncertain how Tfh,…
  • Abstract Number: 1775 • 2019 ACR/ARP Annual Meeting

    Cholesterol Sequestering in Macrophages Contributes to the Lipid Paradox in Chronic Arthritis

    Sandra Pérez-Baos1, Junko Arakawa 2, Raquel Largo 1, Katsunori Ikewaki 2 and Gabriel Herrero-Beaumont 1, 1IIS-Fundación Jiménez Díaz, Madrid, Madrid, Spain, 2National Defense Medical College, Tokorozawa, Saitama, Japan

    Background/Purpose: Patients with active rheumatoid arthritis (RA) have increased cardiovascular mortality, paradoxically associated with reduced circulating lipid levels. Several disease-modifying antirheumatic drugs (DMARDs), such as…
  • Abstract Number: 1776 • 2019 ACR/ARP Annual Meeting

    Causal Effect of TNF-α, IL-12p70, IL-17 Levels on the Risk of Psoriatic Arthritis: A Mendelian Randomization Study

    Dongze WU1, Priscilla Wong 1, Steven H.M. Lam 1, Isaac T. Cheng 1, Edmund K. Li 1, Ling Qin 1 and Lai-Shan Tam 1, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: Biologic agents targeting cytokines including TNF-α, IL-12p70 and IL-17 have been proven to be very effective in treating psoriatic arthritis (PsA).  Nonetheless, whether these…
  • Abstract Number: 1777 • 2019 ACR/ARP Annual Meeting

    The Deubiquitinase TRABID Is a Potential Therapeutic Target in Spondyloarthritis

    Daniele Mauro1, Federica Macaluso 2, Alessandra Nerviani 3, Marie-Astrid Boutet 3, Aroldo Rizzo 4, Riccardo Alessandro 2, Giuliana Guggino 2, Costantino Pitzalis 3 and Francesco Ciccia 5, 1Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, England, United Kingdom, 2University of Palermo, Italy, Palermo, Italy, 3Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, 4Pathology Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy., Palermo, Italy, 5University of Campania L. Vanvitelli, Naples, Italy

    Background/Purpose: Interleukin 12 (IL-12) and 23 (IL-23) may play a pivotal role in the pathogenesis of inflammatory diseases, including Spondyloarthritis (SpA). In mice, the deubiquitinase…
  • Abstract Number: 1778 • 2019 ACR/ARP Annual Meeting

    Entheseal CD90+ SOX9+ Cartilage-like Cells Initiate Spinal Ankylosis in Ankylosing Spondylitis

    Sungsin Jo1, Young Lim Lee 1, Tae-Han Lee 1, Ye-Soo Park 2 and Tae-Hwan Kim 1, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 2Department of Orthopedic Surgery, Hanyang University Medical Center, Guri Hospital,, Guri, Republic of Korea

    Background/Purpose: Enthesitis is characterized by inflammation at the interface where tendon or ligament attaches to the bone and is a representative symptom of ankylosing spondylitis(AS).…
  • « Previous Page
  • 1
  • …
  • 874
  • 875
  • 876
  • 877
  • 878
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology